1. A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer;Adjei;Proc. Am. Soc. Clin. Oncol.,1999
2. The farnesyl protein transferase (FPTase) inhibitor L-778123 in patients with solid cancers;Britten;Proc. Am. Soc. Clin. Oncol.,1999
3. Eskens F, Awada A, Verweij J, Cutler DL, Hanauske A, Piccart. Phase I and pharmacologic study of continuous oral SCH 66336, a novel farnesyl transferase inhibitor, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 1999;18:156a.
4. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule;Hudes;Proc. Am. Soc. Clin. Oncol.,1999
5. Phase I and pharmacokinetic study of SCH666336, a novel FPTI, using a 2-week on, 2-week off schedule;Hurwitz;Proc. Am. Soc. Clin. Oncol.,1999